Lilly Continues To Bet On Alzheimer's With Avid Acquisition
This article was originally published in The Pink Sheet Daily
Unfazed by recent setbacks to semagacestat, Eli Lilly pays $300 million upfront to acquire a diagnostic company with a promising late-stage test for Alzheimer's disease.
You may also be interested in...
Merck will use GE Healthcare’s investigational imaging agent flutemetamol to select patients to enroll in its clinical trial studying the oral BACE inhibitor MK-8931, with a particular emphasis on a future study in Alzheimer’s patients with mild cognitive impairment.
Lilly’s Avid has gained approval for its imaging agent Amyvid, a new tool in the Alzheimer’s disease diagnosis arsenal.
Under CMS’ current policy for PET scans, new imaging agents approved by FDA would have to go through a national coverage analysis before Medicare will pay for them.